Efficacy and safety of RET-specific kinase inhibitors in RET-altered cancers: A systematic review.

RET proto-oncogene encodes receptor tyrosine kinase. Selpercatinib and pralsetinib are the only RET-specific tyrosine kinase inhibitors approved by FDA in RET-altered tumors. We searched PubMed, Embase, Cochrane, WOS and Clinicaltrials.gov. Objective-response, complete-response, and partial-response were 60%-89%, 0-11%, and 55%-89%, respectively with the use of RET-specific drugs. ≥Grade 3 adverse events were seen in 28%-53% of the patients, with hypertension, change in ALT, QT prolongation, neutropenia, and pneumonitis among the common side effects. Hence, selpercatinib and pralsetinib were effective and well tolerated by most of the patients with RET-altered tumors.